Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.67 |
| ▸ | EDNRA | P25101 | 5/20 | 0.50 |
| ▸ | EDNRB | P24530 | 4/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.40 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11975017 | 0.81 | SLC22A12 (1.00) | SLC22A12ACE2 | |
| SCHEMBL27679944 | 0.81 | SLC22A12 (0.50) | SLC22A12KDM4EHCAR3POLBNPSR1 | |
| SCHEMBL27764791 | 0.79 | SLC22A12 (0.49) | SLC22A12EDNRAEDNRBKDM4EHCAR3 | |
| SCHEMBL23809209 | 0.79 | SLC22A12 (0.56) | SLC22A12 | |
| SCHEMBL23809463 | 0.78 | SLC22A12 (0.52) | SLC22A12ACE2KDM4EHCAR3 | |
| SCHEMBL984612 | 0.76 | STAT3 (0.48) | SLC22A12MAPT | |
| SCHEMBL18993212 | 0.76 | CYP19A1 (0.42) | SLC22A12 | |
| SCHEMBL23809523 | 0.74 | SLC22A12 (0.51) | SLC22A12ACE2KDM4EHCAR3 | |
| SCHEMBL18705804 | 0.74 | SLC22A12 (0.46) | SLC22A12KDM4EHCAR3POLB | |
| SCHEMBL23809482 | 0.72 | SLC22A12 (0.49) | SLC22A12ACE2KDM4EHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | SLC22A12 3136/4885EDNRA 3551/4885EDNRB 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.